FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136435269> ?p ?o ?g. }

• W3136435269 abstract "Abstract Aims Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a new class of antidiabetic drugs, are nephroprotective in case of diabetes, but whether a similar beneficial effect may be detectable also in case of chronic non-diabetic kidney diseases remains still unknown. The aim of this study was to evaluate the effects of empagliflozin, a SGLT-2 inhibitor, on the progression of cyclosporine nephropathy, in the absence of diabetes. Methods Sprague Dawley rats ( n = 27) have been fed with low-salt diet starting 10 days before the beginning and finished at the end of the experimental period. Cyclosporine-A (CsA, 15 mg/kg/day, intraperitoneal injection, n = 8) and CsA plus empagliflozin (Empa, 10 mg/kg/day, per os, n = 7) were administered for 4 weeks. The control groups were treated with placebo (Control, n = 7) or empagliflozin (Control + Empa, n = 5). Blood pressure (plethysmographic method) was measured at the beginning and at the end of the experimental period. At the end of the experimental protocol, the kidneys were excised for histomorphometric analysis of renal fibrosis and for immunohistochemical evaluation of inflammatory infiltrates (monocytes/macrophages), type I and type IV collagen expression, and tyrosine hydroxylase expression, used as marker of sympathetic nerve activity. Results CsA-treated rats showed a significant increase ( p < 0.01) in blood pressure, which was reduced by administration of empagliflozin ( p < 0.05). CsA administration caused an increase in glomerular and tubulo-interstitial fibrosis ( p < 0.05), renal inflammatory infiltrates ( p < 0.05), type I and type IV collagen expression ( p < 0.01), and tyrosine hydroxylase expression ( p < 0.01) as compared to the control rats and control + Empa-treated rats. Treatment with empagliflozin in CsA-treated rats reduced glomerular ( p < 0.01) and tubulo-interstitial fibrosis ( p < 0.05), type I and type IV collagen expression ( p < 0.01), inflammatory cell infiltration ( p < 0.01) and tyrosine hydroxylase expression ( p < 0.05), as compared to rats treated with CsA. Conclusion Empagliflozin administration caused a reduction in blood pressure in CsA-treated rats and showed a protective effect on CsA nephropathy by decreasing renal fibrosis, type I and type IV collagen expression, macrophage infiltration and tyrosine hydroxylase expression. These data suggest that empagliflozin promotes nephroprotection also in non-diabetic kidney disease." @default.
• W3136435269 created "2021-03-29" @default.
• W3136435269 creator A5001341098 @default.
• W3136435269 creator A5004292353 @default.
• W3136435269 creator A5006683195 @default.
• W3136435269 creator A5034591043 @default.
• W3136435269 creator A5038566234 @default.
• W3136435269 creator A5044484087 @default.
• W3136435269 creator A5050669429 @default.
• W3136435269 creator A5060075966 @default.
• W3136435269 creator A5060290724 @default.
• W3136435269 creator A5067743960 @default.
• W3136435269 date "2021-03-24" @default.
• W3136435269 modified "2023-10-02" @default.
• W3136435269 title "Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy" @default.
• W3136435269 cites W1893139299 @default.
• W3136435269 cites W1970192183 @default.
• W3136435269 cites W1981837967 @default.
• W3136435269 cites W1983097616 @default.
• W3136435269 cites W1990921191 @default.
• W3136435269 cites W2001008133 @default.
• W3136435269 cites W2003655983 @default.
• W3136435269 cites W2054864494 @default.
• W3136435269 cites W2062162902 @default.
• W3136435269 cites W2076230481 @default.
• W3136435269 cites W2079097007 @default.
• W3136435269 cites W2091660015 @default.
• W3136435269 cites W2091874442 @default.
• W3136435269 cites W2125750883 @default.
• W3136435269 cites W2136728678 @default.
• W3136435269 cites W2218522301 @default.
• W3136435269 cites W2231922283 @default.
• W3136435269 cites W2342735140 @default.
• W3136435269 cites W2424539745 @default.
• W3136435269 cites W2504697643 @default.
• W3136435269 cites W2527027365 @default.
• W3136435269 cites W2530979034 @default.
• W3136435269 cites W2560643142 @default.
• W3136435269 cites W2586198488 @default.
• W3136435269 cites W2588592529 @default.
• W3136435269 cites W2595993285 @default.
• W3136435269 cites W2602271880 @default.
• W3136435269 cites W2615515448 @default.
• W3136435269 cites W2618856448 @default.
• W3136435269 cites W2618918882 @default.
• W3136435269 cites W2621172390 @default.
• W3136435269 cites W2624457286 @default.
• W3136435269 cites W2626446274 @default.
• W3136435269 cites W2800723402 @default.
• W3136435269 cites W2808725516 @default.
• W3136435269 cites W2883419804 @default.
• W3136435269 cites W2885904108 @default.
• W3136435269 cites W2887628755 @default.
• W3136435269 cites W2909964452 @default.
• W3136435269 cites W2921862544 @default.
• W3136435269 cites W2939222610 @default.
• W3136435269 cites W2949665037 @default.
• W3136435269 cites W2979968423 @default.
• W3136435269 cites W2995476775 @default.
• W3136435269 cites W2999945678 @default.
• W3136435269 cites W3000397625 @default.
• W3136435269 doi "https://doi.org/10.1007/s00592-021-01681-2" @default.
• W3136435269 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8272713" @default.
• W3136435269 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33760995" @default.
• W3136435269 hasPublicationYear "2021" @default.
• W3136435269 type Work @default.
• W3136435269 sameAs 3136435269 @default.
• W3136435269 citedByCount "17" @default.
• W3136435269 countsByYear W31364352692021 @default.
• W3136435269 countsByYear W31364352692022 @default.
• W3136435269 countsByYear W31364352692023 @default.
• W3136435269 crossrefType "journal-article" @default.
• W3136435269 hasAuthorship W3136435269A5001341098 @default.
• W3136435269 hasAuthorship W3136435269A5004292353 @default.
• W3136435269 hasAuthorship W3136435269A5006683195 @default.
• W3136435269 hasAuthorship W3136435269A5034591043 @default.
• W3136435269 hasAuthorship W3136435269A5038566234 @default.
• W3136435269 hasAuthorship W3136435269A5044484087 @default.
• W3136435269 hasAuthorship W3136435269A5050669429 @default.
• W3136435269 hasAuthorship W3136435269A5060075966 @default.
• W3136435269 hasAuthorship W3136435269A5060290724 @default.
• W3136435269 hasAuthorship W3136435269A5067743960 @default.
• W3136435269 hasBestOaLocation W31364352691 @default.
• W3136435269 hasConcept C126322002 @default.
• W3136435269 hasConcept C134018914 @default.
• W3136435269 hasConcept C2775887513 @default.
• W3136435269 hasConcept C2777180221 @default.
• W3136435269 hasConcept C2779922275 @default.
• W3136435269 hasConcept C2780091579 @default.
• W3136435269 hasConcept C2780559512 @default.
• W3136435269 hasConcept C2781184683 @default.
• W3136435269 hasConcept C555293320 @default.
• W3136435269 hasConcept C71924100 @default.
• W3136435269 hasConceptScore W3136435269C126322002 @default.
• W3136435269 hasConceptScore W3136435269C134018914 @default.
• W3136435269 hasConceptScore W3136435269C2775887513 @default.
• W3136435269 hasConceptScore W3136435269C2777180221 @default.
• W3136435269 hasConceptScore W3136435269C2779922275 @default.
• W3136435269 hasConceptScore W3136435269C2780091579 @default.
• W3136435269 hasConceptScore W3136435269C2780559512 @default.

• next